Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group and keeping the price target at $12.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Robert Burns has given his Buy rating due to a combination of factors that highlight the potential of Replimune Group’s RP1 + Opdivo therapy. The company’s recent resubmission of the Biologics License Application for this combination therapy, aimed at treating advanced melanoma, is a key factor. The FDA has set a decision date for April 2026, which indicates progress towards potential approval.
The clinical trial results from the IGNYTE study further bolster confidence in the therapy’s efficacy. The trial demonstrated a notable objective response rate and a median duration of response, which are promising compared to existing treatments. Additionally, the safety profile of RP1 + Opdivo is relatively favorable, with fewer severe adverse events compared to other therapies. These elements, combined with Replimune’s financial position and operational runway, support the Buy rating and the positive outlook for the company’s stock.
In another report released on October 22, Leerink Partners also upgraded the stock to a Buy with a $13.00 price target.